Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.

McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S, Muschel RJ, Ng SM, Panakis N, Prevo R, Strauss VY, Stuart R, Tacconi EMC, Vallis KA, McKenna WG, Macpherson RE, Higgins GS.

Eur J Cancer. 2019 May;113:87-95. doi: 10.1016/j.ejca.2019.03.015. Epub 2019 Apr 13.

2.

CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner.

Prevo R, Pirovano G, Puliyadi R, Herbert KJ, Rodriguez-Berriguete G, O'Docherty A, Greaves W, McKenna WG, Higgins GS.

Cell Cycle. 2018;17(12):1513-1523. doi: 10.1080/15384101.2018.1491236. Epub 2018 Jul 25.

3.

Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity.

Rodriguez-Berriguete G, Granata G, Puliyadi R, Tiwana G, Prevo R, Wilson RS, Yu S, Buffa F, Humphrey TC, McKenna WG, Higgins GS.

Nucleic Acids Res. 2018 Sep 6;46(15):7731-7746. doi: 10.1093/nar/gky569.

4.

STING-Dependent Interferon-λ1 Induction in HT29 Cells, a Human Colorectal Cancer Cell Line, After Gamma-Radiation.

Chen J, Markelc B, Kaeppler J, Ogundipe VML, Cao Y, McKenna WG, Muschel RJ.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):97-106. doi: 10.1016/j.ijrobp.2018.01.091. Epub 2018 Feb 3.

PMID:
29619982
5.

Oxidative Phosphorylation as an Emerging Target in Cancer Therapy.

Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS.

Clin Cancer Res. 2018 Jun 1;24(11):2482-2490. doi: 10.1158/1078-0432.CCR-17-3070. Epub 2018 Feb 2. Review.

6.

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.

Pirovano G, Ashton TM, Herbert KJ, Bryant RJ, Verrill CL, Cerundolo L, Buffa FM, Prevo R, Harrap I, Ryan AJ, Macaulay V, McKenna WG, Higgins GS.

Br J Cancer. 2017 Aug 8;117(4):503-512. doi: 10.1038/bjc.2017.197. Epub 2017 Jul 4.

7.

18 F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study.

McGowan DR, Macpherson RE, Hackett SL, Liu D, Gleeson FV, McKenna WG, Higgins GS, Fenwick JD.

Med Phys. 2017 Sep;44(9):4665-4676. doi: 10.1002/mp.12416. Epub 2017 Jul 21.

8.

Depletion of signal recognition particle 72kDa increases radiosensitivity.

Prevo R, Tiwana GS, Maughan TS, Buffa FM, McKenna WG, Higgins GS.

Cancer Biol Ther. 2017 Jun 3;18(6):425-432. doi: 10.1080/15384047.2017.1323587. Epub 2017 May 11.

9.

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.

Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, Muschel RJ, Fokas E.

EMBO Mol Med. 2017 Feb;9(2):167-180. doi: 10.15252/emmm.201606674.

10.

Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Diana A, Wang LM, D'Costa Z, Azad A, Silva MA, Soonawalla Z, Allen P, Liu S, McKenna WG, Muschel RJ, Fokas E.

Oncotarget. 2016 Nov 8;7(45):72819-72832. doi: 10.18632/oncotarget.12022.

11.

Comments on potential health effects of MRI-induced DNA lesions: quality is more important to consider than quantity.

Hill MA, O'Neill P, McKenna WG.

Eur Heart J Cardiovasc Imaging. 2016 Nov;17(11):1230-1238. Epub 2016 Aug 22. Review.

12.

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.

Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, Stratford M, Muschel RJ, Higgins GS, McKenna WG.

Nat Commun. 2016 Jul 25;7:12308. doi: 10.1038/ncomms12308.

13.

Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.

Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ, Fokas E.

Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.

14.

Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors.

Higgins GS, Krause M, McKenna WG, Baumann M.

Recent Results Cancer Res. 2016;198:107-22. doi: 10.1007/978-3-662-49651-0_5. Review.

PMID:
27318683
15.

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.

Al-Assar O, Bittner MI, Lunardi S, Stratford MR, McKenna WG, Brunner TB.

Radiother Oncol. 2016 May;119(2):300-5. doi: 10.1016/j.radonc.2016.03.024. Epub 2016 May 28.

PMID:
27247056
16.

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.

Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB.

Radiother Oncol. 2016 May;119(2):306-11. doi: 10.1016/j.radonc.2016.03.021. Epub 2016 Apr 23.

17.

Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.

Hill EJ, Roberts C, Franklin JM, Enescu M, West N, MacGregor TP, Chu KY, Boyle L, Blesing C, Wang LM, Mukherjee S, Anderson EM, Brown G, Dutton S, Love SB, Schnabel JA, Quirke P, Muschel R, McKenna WG, Partridge M, Sharma RA.

Clin Cancer Res. 2016 Apr 15;22(8):1922-31. doi: 10.1158/1078-0432.CCR-15-1489. Epub 2016 Feb 9.

18.

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.

Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S, O'Neill E, Mukherjee S, McKenna WG, Muschel R, Fokas E.

Oncotarget. 2016 Jan 26;7(4):4183-94. doi: 10.18632/oncotarget.6770.

19.

Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.

Tiwana GS, Prevo R, Buffa FM, Yu S, Ebner DV, Howarth A, Folkes LK, Budwal B, Chu KY, Durrant L, Muschel RJ, McKenna WG, Higgins GS.

Oncotarget. 2015 Mar 20;6(8):5978-89.

20.

Drug radiotherapy combinations: review of previous failures and reasons for future optimism.

Higgins GS, O'Cathail SM, Muschel RJ, McKenna WG.

Cancer Treat Rev. 2015 Feb;41(2):105-13. doi: 10.1016/j.ctrv.2014.12.012. Epub 2015 Jan 3. Review.

PMID:
25579753
21.

Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.

Fokas E, O'Neill E, Gordon-Weeks A, Mukherjee S, McKenna WG, Muschel RJ.

Biochim Biophys Acta. 2015 Jan;1855(1):61-82. doi: 10.1016/j.bbcan.2014.12.001. Epub 2014 Dec 7. Review.

PMID:
25489989
22.

Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells.

Al-Assar O, Demiciorglu F, Lunardi S, Gaspar-Carvalho MM, McKenna WG, Muschel RM, Brunner TB.

Radiother Oncol. 2014 May;111(2):243-51. doi: 10.1016/j.radonc.2014.03.014. Epub 2014 Apr 26.

PMID:
24780634
23.

A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy.

Fokas E, Eccles C, Patel N, Chu KY, Warren S, McKenna WG, Brunner TB.

Radiother Oncol. 2013 May;107(2):200-6. doi: 10.1016/j.radonc.2013.04.010. Epub 2013 May 3.

PMID:
23647755
24.

Targeting ATR in DNA damage response and cancer therapeutics.

Fokas E, Prevo R, Hammond EM, Brunner TB, McKenna WG, Muschel RJ.

Cancer Treat Rev. 2014 Feb;40(1):109-17. doi: 10.1016/j.ctrv.2013.03.002. Epub 2013 Apr 11. Review.

PMID:
23583268
25.

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.

Prevo R, Fokas E, Reaper PM, Charlton PA, Pollard JR, McKenna WG, Muschel RJ, Brunner TB.

Cancer Biol Ther. 2012 Sep;13(11):1072-81. doi: 10.4161/cbt.21093. Epub 2012 Jul 24.

26.

The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.

Fokas E, McKenna WG, Muschel RJ.

Cancer Metastasis Rev. 2012 Dec;31(3-4):823-42. doi: 10.1007/s10555-012-9394-4. Review.

PMID:
22825313
27.

Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta.

Nicolay NH, Carter R, Hatch SB, Schultz N, Prevo R, McKenna WG, Helleday T, Sharma RA.

Carcinogenesis. 2012 Nov;33(11):2026-34. doi: 10.1093/carcin/bgs239. Epub 2012 Jul 20.

28.

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.

Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, McKenna WG, Hammond EM.

Br J Cancer. 2012 Jul 10;107(2):291-9. doi: 10.1038/bjc.2012.265. Epub 2012 Jun 19.

29.

Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.

Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, Zeng L, Ou G, Zhu Y, Yoshimura M, McKenna WG, Muschel RJ, Hiraoka M.

Nat Commun. 2012 Apr 17;3:783. doi: 10.1038/ncomms1786. Erratum in: Nat Commun. 2013;4. doi:10.1038/ncomms3314.

30.

NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.

Fokas E, Yoshimura M, Prevo R, Higgins G, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Radiat Oncol. 2012 Mar 27;7:48. doi: 10.1186/1748-717X-7-48.

31.

Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.

Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ.

Cancer Res. 2012 Jan 1;72(1):239-48. doi: 10.1158/0008-5472.CAN-11-2263. Epub 2011 Nov 22.

32.

Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.

Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ.

Clin Cancer Res. 2012 Jan 1;18(1):161-9. doi: 10.1158/1078-0432.CCR-11-1413. Epub 2011 Nov 7.

33.

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.

Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T.

Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19. Review. No abstract available.

34.

Overexpression of POLQ confers a poor prognosis in early breast cancer patients.

Higgins GS, Harris AL, Prevo R, Helleday T, McKenna WG, Buffa FM.

Oncotarget. 2010 Jul;1(3):175-84.

35.

Radiotherapy research priorities for the UK.

Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group.

Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9. doi: 10.1016/j.clon.2010.03.006. Epub 2010 Apr 2. No abstract available.

PMID:
20363111
36.

A small interfering RNA screen of genes involved in DNA repair identifies tumor-specific radiosensitization by POLQ knockdown.

Higgins GS, Prevo R, Lee YF, Helleday T, Muschel RJ, Taylor S, Yoshimura M, Hickson ID, Bernhard EJ, McKenna WG.

Cancer Res. 2010 Apr 1;70(7):2984-93. doi: 10.1158/0008-5472.CAN-09-4040. Epub 2010 Mar 16. Erratum in: Cancer Res. 2010 May 1;70(9):3853.

37.

Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers.

Al-Assar O, Muschel RJ, Mantoni TS, McKenna WG, Brunner TB.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1216-25. doi: 10.1016/j.ijrobp.2009.07.001.

PMID:
19857785
38.

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.

Yang J, Parsons J, Nicolay NH, Caporali S, Harrington CF, Singh R, Finch D, D'Atri S, Farmer PB, Johnston PG, McKenna WG, Dianov G, Sharma RA.

Oncogene. 2010 Jan 21;29(3):463-8. doi: 10.1038/onc.2009.327. Epub 2009 Oct 19.

PMID:
19838217
39.

Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.

Parsons JL, Tait PS, Finch D, Dianova II, Edelmann MJ, Khoronenkova SV, Kessler BM, Sharma RA, McKenna WG, Dianov GL.

EMBO J. 2009 Oct 21;28(20):3207-15. doi: 10.1038/emboj.2009.243. Epub 2009 Aug 27.

40.

Tumor vascular changes mediated by inhibition of oncogenic signaling.

Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ.

Cancer Res. 2009 Aug 1;69(15):6347-54. doi: 10.1158/0008-5472.CAN-09-0657. Epub 2009 Jul 21.

41.

Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity.

Prevo R, Deutsch E, Sampson O, Diplexcito J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S, Bernhard EJ.

Cancer Res. 2008 Jul 15;68(14):5915-23. doi: 10.1158/0008-5472.CAN-08-0757.

42.

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG.

J Clin Oncol. 2008 Jun 1;26(16):2699-706. doi: 10.1200/JCO.2007.15.2355.

PMID:
18509182
43.

Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1.

Cordes N, Frick S, Brunner TB, Pilarsky C, Grützmann R, Sipos B, Klöppel G, McKenna WG, Bernhard EJ.

Oncogene. 2007 Oct 18;26(48):6851-62. Epub 2007 Apr 30.

PMID:
17471232
44.

Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells.

Cengel KA, Voong KR, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna WG, Bernhard EJ.

Neoplasia. 2007 Apr;9(4):341-8.

45.

"Hood ornament" or "V-10 engine"? Myths and realities regarding physician-scientists in academic radiation oncology departments.

Kao GD, McKenna WG.

J Am Coll Radiol. 2004 Aug;1(8):539-44. No abstract available.

PMID:
17411649
46.

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.

Brunner TB, Cengel KA, Hahn SM, Wu J, Fraker DL, McKenna WG, Bernhard EJ.

Cancer Res. 2005 Sep 15;65(18):8433-41.

47.

HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ.

Cancer Res. 2005 Sep 15;65(18):8256-65.

48.

Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.

Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ, Bernhard EJ.

Cancer Res. 2005 Sep 1;65(17):7902-10.

49.

Molecular targets for altering radiosensitivity: lessons from Ras as a pre-clinical and clinical model.

Cengel KA, McKenna WG.

Crit Rev Oncol Hematol. 2005 Aug;55(2):103-16. Review.

PMID:
16006139
50.

DR5 knockout mice are compromised in radiation-induced apoptosis.

Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, El-Deiry WS.

Mol Cell Biol. 2005 Mar;25(5):2000-13.

Supplemental Content

Loading ...
Support Center